Multimodality imaging in carcinoid heart disease.
cardiac remodelling
echocardiography
tricuspid valve disease
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
Historique:
received:
26
03
2019
revised:
08
04
2019
accepted:
14
04
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
28
6
2019
Statut:
epublish
Résumé
Neuroendocrine neoplasms arise from the gastrointestinal tract and can lead to carcinoid syndrome. Carcinoid heart disease affects more than half of these patients and is the initial presentation of carcinoid syndrome in up to 20 % of patients. Carcinoid heart disease typically leads to valve dysfunction, but in rare instances, carcinoid tumours can also metastasise to the endocardium and myocardium. Cardiovascular imaging plays an integral role in the diagnosis and prognosis of carcinoid heart disease. The use of multimodality imaging techniques including echocardiography, cardiac MRI, cardiovascular CT and positron emission tomography have allowed for a more comprehensive assessment of carcinoid heart disease. In this review, we discuss the features of carcinoid heart disease observed on multimodality imaging, indications for obtaining imaging studies and their role in carcinoid heart disease management.
Identifiants
pubmed: 31245014
doi: 10.1136/openhrt-2019-001060
pii: openhrt-2019-001060
pmc: PMC6560671
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e001060Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Tex Heart Inst J. 2000;27(4):405-7
pubmed: 11198317
Circulation. 1964 Feb;29:253-7
pubmed: 14119390
Heart. 2004 Oct;90(10):1224-8
pubmed: 15367531
Circulation. 2005 Nov 22;112(21):3320-7
pubmed: 16286584
Curr Cardiol Rep. 2006 Mar;8(2):96-101
pubmed: 16524535
Am Heart J. 2006 May;151(5):1129.e1-6
pubmed: 16644350
J Nucl Med. 2007 Apr;48(4):508-18
pubmed: 17401086
Congenit Heart Dis. 2007 Jan-Feb;2(1):27-31
pubmed: 18377513
Am J Cardiol. 2008 Oct 1;102(7):938-42
pubmed: 18805126
Anesth Analg. 2009 May;108(5):1463-4
pubmed: 19372320
Clin Cardiol. 2009 Jun;32(6):E92-3
pubmed: 19382278
Clin Radiol. 2009 Aug;64(8):761-6
pubmed: 19589414
Circ Cardiovasc Imaging. 2010 Jan;3(1):103-11
pubmed: 19920029
Eur Heart J. 2010 Jun;31(12):1520-8
pubmed: 20233787
Eur J Echocardiogr. 2011 Jan;12(1):E4
pubmed: 20729293
Echocardiography. 2010 Oct;27(9):1098-105
pubmed: 21039812
J Cardiovasc Comput Tomogr. 2011 Jan-Feb;5(1):16-29
pubmed: 21051311
J Am Soc Echocardiogr. 2011 Jun;24(6):644-50
pubmed: 21440415
Acta Cardiol. 2012 Apr;67(2):245-8
pubmed: 22641985
Curr Treat Options Cardiovasc Med. 2013 Oct;15(5):544-55
pubmed: 23955119
Circulation. 1988 Feb;77(2):264-9
pubmed: 2448062
J Saudi Heart Assoc. 2014 Jan;26(1):51-5
pubmed: 24578601
Circulation. 2014 Jun 10;129(23):2440-92
pubmed: 24589852
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
J Am Coll Cardiol. 2015 Mar 24;65(11):1078-88
pubmed: 25790878
Neuroendocrinology. 2015;101(4):263-73
pubmed: 25871411
JACC Cardiovasc Interv. 2015 Aug 24;8(10):e161-3
pubmed: 26315750
Acta Oncol. 1989;28(3):389-402
pubmed: 2663049
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):45-57
pubmed: 26971843
Tex Heart Inst J. 2016 Aug 01;43(4):341-4
pubmed: 27547148
J Am Coll Cardiol. 2017 Mar 14;69(10):1288-1304
pubmed: 28279296
Eur Heart J Cardiovasc Imaging. 2017 Oct 1;18(10):1090-1121
pubmed: 28510718
Circulation. 1993 Apr;87(4):1188-96
pubmed: 7681733
J Am Coll Cardiol. 1995 Feb;25(2):410-6
pubmed: 7829795
J Am Coll Cardiol. 1998 Oct;32(4):1017-22
pubmed: 9768727